Dr. Amir Hossein Lebastchi, MD

Dr. Lebastchi practices at USC Care Medical Group, Inc in Glendale, California.

Dr. Lebastchi's NPI, 1972895142, was assigned on May 6, 2011. Dr. Lebastchi graduated from University of Hamburg FOM in 2009. Dr. Lebastchi holds California license A169779.

Dr. Lebastchi's primary practice is USC Care Medical Group, Inc, at 1808 Verdugo Blvd, Glendale, CA 91208 in Los Angeles County. The practice phone is (323) 442-5955.

Dr. Lebastchi's primary practice is USC Care Medical Group, Inc in Glendale, California. Dr. Lebastchi is also affiliated with USC Verdugo Hills Hospital. The medical group on file is USC Care Medical Group. Dmand AI also links Dr. Lebastchi to 1 more hospital, 1 group practice or clinic and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lebastchi practices, 4 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Lebastchi's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Lebastchi is board certified in urology by the American Board of Urology. Dmand AI has Dr. Lebastchi's licenses on file in 5 states: California, District of Columbia, Connecticut, Maryland and Michigan.

Dmand AI lists enlarged prostate, erectile dysfunction, kidney cysts, prostate surgery, urinary endoscopy, urine flow blockage and UTI among the conditions Dr. Lebastchi treats.

CMS data shows 1,340 Medicare services from Dr. Lebastchi across 15 procedure codes in 2024, for 293 Medicare patients. Medicare paid $110,771 for them.

CMS counts 293 Medicare patients who saw Dr. Lebastchi in 2024. The largest group is 65 to 74, with 164 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 1.32, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lebastchi's median patient age at 71, with 5% women.

In 2024, Dr. Lebastchi wrote 141 Medicare Part D claims for 49 patients. 96% of them were for generic drugs. CMS names the drug for 117 of them, across 4 drugs with 11 or more claims each, at $733 in total drug cost. In 2023, CMS named 204 claims across 3 drugs.

Dr. Lebastchi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lebastchi as offering telehealth.

Prostate resection: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 24 papers to Dr. Lebastchi, published from 2011 to 2023. 2020 was the busiest year, with 6. The most frequent topics are Prostatic Neoplasms, Multiparametric Magnetic Resonance Imaging and Prostate-Specific Antigen. Dr. Lebastchi's most frequent co-authors are Peter Anthony Pinto, MD, Bradford J. Wood, MD and Sandeep Gurram, MD.

CMS Open Payments shows 359 general payments to Dr. Lebastchi from 20 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 84% of the total. Edap Technomed Inc paid the most, $422,492.

Dr. Lebastchi graduated from University of Hamburg FOM in 2009.

Dr. Lebastchi is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.